IDO1 Human shRNA Plasmid Kit (Locus ID 3620)
CAT#: TL312147
IDO1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
Cited in 3 publications. |
Product images
CNY 1,999.00
CNY 2,700.00
CNY 4,070.00
Specifications
Product Data | |
Product Name | IDO1 Human shRNA Plasmid Kit (Locus ID 3620) |
Locus ID | 3620 |
UniProt ID | P14902 |
Synonyms | IDO; IDO-1; INDO |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | IDO1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 3620). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_002164, NM_002164.1, NM_002164.2, NM_002164.3, NM_002164.4, NM_002164.5, BC027882, BC027882.1, NM_002164.6 |
Summary | This gene encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme is thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. Through its expression in dendritic cells, monocytes, and macrophages this enzyme modulates T-cell behavior by its peri-cellular catabolization of the essential amino acid tryptophan.[provided by RefSeq, Feb 2011] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (3)
The use of this RNAi has been cited in the following citations: |
---|
Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
,null,
Cancer & metabolism
,PubMed ID 37226257
[IDO1]
|
Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer
,Nguyen, DJ;Theodoropoulos, G;Li, YY;Wu, C;Sha, W;Feun, LG;Lampidis, TJ;Savaraj, N;Wangpaichitr, M;,
Mol. Cancer Res.
,PubMed ID 31628200
[IDO1]
|
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
,Liu, Y;Liang, X;Yin, X;Lv, J;Tang, K;Ma, J;Ji, T;Zhang, H;Dong, W;Jin, X;Chen, D;Li, Y;Zhang, S;Xie, HQ;Zhao, B;Zhao, T;Lu, J;Hu, ZW;Cao, X;Qin, FX;Huang, B;,
Nat Commun
,PubMed ID 28488695
[IDO1]
|
Documents
Product Manuals |
FAQs |
SDS |